The IAM/ktMINE US Patent Elite share tracker shows that a composite of the publicly-quoted companies in the rankings out-performed the NASDAQ, the Tokyo Stock Exchange and Germany's Dax Index Read more
Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more
Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more
The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players Read more
Eran Zur and his team add a portfolio of patents to their portfolio which have survived multiple attacks at the PTAB and read on a technology area of growing importance Read more
After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101 Read more
The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake
@IAM_magazine RT @jwschindler: New patent lawsuit filed by Pro-Troll Inc in Minnesota. But it's not that kind of trolling - the plaintiff is asserting th… Read more
